(Q43610447)

25 November 2017

Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients (English)

1 reference

25 November 2017

1 reference

lymphoblastic leukemia

1 reference

Hamaki T

1

1 reference

25 November 2017

Kami M

2

1 reference

25 November 2017

Kanda Y

3

1 reference

25 November 2017

Yuji K

4

1 reference

25 November 2017

Inamoto Y

5

1 reference

25 November 2017

Kishi Y

6

1 reference

25 November 2017

Nakai K

7

1 reference

25 November 2017

Nakayama I

8

1 reference

25 November 2017

Murashige N

9

1 reference

25 November 2017

Abe Y

10

1 reference

25 November 2017

Ueda Y

11

1 reference

25 November 2017

Hino M

12

1 reference

25 November 2017

Inoue T

13

1 reference

25 November 2017

Ago H

14

1 reference

25 November 2017

Hidaka M

15

1 reference

25 November 2017

Hayashi T

16

1 reference

25 November 2017

Yamane T

17

1 reference

25 November 2017

Uoshima N

18

1 reference

25 November 2017

Miyakoshi S

19

1 reference

25 November 2017

Taniguchi S

20

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

Bone Marrow Transplantation

25 November 2017

1 reference

25 November 2017

35

1 reference

25 November 2017

6

1 reference

25 November 2017

549-556

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704776

25 November 2017

0 references

cites work

Chemotherapy versus transplantation in acute leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

Bone marrow transplant in Ph+ ALL patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: prolonged survival associated with acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

BONE-MARROW TRANSPLANTATION IN HIGH-RISK ACUTE LYMPHOBLASTIC LEUKAEMIA IN FIRST AND SECOND REMISSION

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP experience. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Associazione Italiana Ematologìa ed Ocologia Pediatrica

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

7 January 2021

Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

7 January 2021

Donor leukocyte infusions in acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

7 January 2021

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

7 January 2021

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

7 January 2021

Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

7 January 2021

Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

7 January 2021

Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

7 January 2021

Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704776

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704776

1 reference

Dimensions Publication ID

25 November 2017

0 references

1 reference